Doxorubicin · Medac GmbH
In the event of an inadvertent temperature excursion the following data may be used:
The manufacturer has in-house stability data to support a temperature excursion of up to 12 hours to a maximum temperature of 25°C. Extended stability data are available on request from the manufacturer.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
Myocet · Teva
Contact Teva in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.
Doxorubicin · Pfizer Limited
Contact Pfizer Limited in all cases where a deviation from the recommended storage conditions has occurred.
Refer to the current BNF for company contact details
Lactation Safety Information
Livatag (doxorubicin nanoparticles) · Hepatocellular carcinoma (HCC) after treatment with, or intolerance to, sorafenib
Development and Regulatory status
Mar 18: Company to conclude the development of Livatag in liver cancer according to 2017 annual report .
May 14: Received Fast Track designation from the FDA for the treatment of hepatocellular carcinoma (primary liver cancer) after treatment with Sorafenib. 
Apr 15: Onxeo announced it is seeking partners for the development of Livatag® .
Oct 04: Granted orphan drug status in the EU for treatment of hepatocellular carcinoma .